Difference between revisions of "Part:BBa K364307:Experience"

(→‎Applications of BBa_K364307)
(→‎Ligand)
 
(8 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
how you used this part and how it worked out.
 
how you used this part and how it worked out.
  
−
===Physiological functions===
+
 
 +
 
 +
===Physiological effects of ER===
 
In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.
 
In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.
  
 +
===Potential applications of ER DBD===
 +
ER-DBD can be fused with various LBDs in order to get heterogenous composite Nuclear Receptors. With addition of the LBD's ligand the receptor can bind to Estrogen Receptor Response element and activate downstream gene expression.
 
===Applications of BBa_K364307===
 
===Applications of BBa_K364307===
−
This part can be fused with different LBDs to get a composite nuclear receptor binding to the Estrogen Receptor Response element. With the addition of the LBD's Ligand the receptor binds to the Estrogen Receptor Response Element and leads to downstream gene expression.
 
−
 
−
===References===
 
−
Dahlman-Wright K, Cavailles V, Fuqua SA, Jordan VC, Katzenellenbogen JA, Korach KS, Maggi A, Muramatsu M, Parker MG, Gustafsson JA (2006). "International Union of Pharmacology. LXIV. Estrogen receptors". Pharmacol. Rev. 58 (4): 773–81. doi:10.1124/pr.58.4.8.
 
−
 
−
Levin ER (2005). "Integration of the extranuclear and nuclear actions of estrogen". Mol. Endocrinol. 19 (8): 1951–9. doi:10.1210/me.2004-0390.
 
  
−
Leung YK, Mak P, Hassan S, Ho SM (August 2006). "Estrogen receptor (ER)-beta isoforms: a key to understanding ER-beta signaling". Proc Natl Acad Sci USA 103 (35): 13162–7.
 
  
−
Deroo BJ, Korach KS (2006). "Estrogen receptors and human disease". J. Clin. Invest. 116 (3): 561–7.
 
  
 
===User Reviews===
 
===User Reviews===

Latest revision as of 01:53, 26 October 2010

This experience page is provided so that any user may enter their experience using this part.
Please enter how you used this part and how it worked out.


Physiological effects of ER

In the absence of hormone, estrogen receptors are largely located in the cytosol. Hormone binding to the receptor triggers a number of events starting with migration of the receptor from the cytosol into the nucleus, dimerization of the receptor, and subsequent binding of the receptor dimer to specific sequences of DNA. Some of the effects in humans: Createing proliferative endometrium,breast cell stimulation, increased body fat and weight gain, salt and fluid retention, increased risk of blood clots.

Potential applications of ER DBD

ER-DBD can be fused with various LBDs in order to get heterogenous composite Nuclear Receptors. With addition of the LBD's ligand the receptor can bind to Estrogen Receptor Response element and activate downstream gene expression.

Applications of BBa_K364307

User Reviews

UNIQaea00a1d3a3e9a8b-partinfo-00000000-QINU UNIQaea00a1d3a3e9a8b-partinfo-00000001-QINU